IL-12 transduced TIL

IL-12 transduced TIL refers to autologous tumor-infiltrating lymphocytes (TIL) that have been genetically engineered to express and secrete interleukin-12 (IL-12), typically under the control of an inducible promoter such as the nuclear factor of activated T cells (NFAT). This cell therapy is designed to deliver high concentrations of IL-12 directly within the tumor microenvironment upon activation, thereby enhancing local antitumor immune responses while minimizing systemic toxicity associated with recombinant or systemic IL-12 administration. The mechanism involves both innate and adaptive immunity; secreted IL-12 promotes Th1 differentiation, increases IFN-gamma production by NK and T cells, enhances cytotoxicity of CD8+ and CD4+ cells, reprograms immunosuppressive myeloid-derived suppressor cells in the tumor microenvironment into immunostimulatory phenotypes, and exerts antiangiogenic effects[1][2][3][4]. Clinical trials in metastatic melanoma have shown objective responses at higher cell doses but also revealed significant toxicities attributable to high levels of secreted IL-12[2][4].

Other names

IL-12 engineered tumor-infiltrating lymphocytesIL12 engineered tumor-infiltrating lymphocytesIL 12 engineered tumor-infiltrating lymphocytesinducible IL-12 TILNFAT.IL12-TIL